Checkpoint immunotherapies such as monotherapy and combination therapy utilizing anti-PD1 and anti-CTLA4 antibodies have been remarkably successful in other cancers but have been ineffective in pancreatic cancer (Brahmer et al., 2012; O'Reilly et al., 2019a; O'Reilly et al., 2019b; Royal et al., 2010). This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.